Cardiac magnetic resonance imaging: Choice of the year: Which imaging modality is best for evaluation of myocardial ischemia? (MRI-side)

Circulation Journal

Volumn 75, Issue 3, 2011, Pages 724-731

  Cheung, Stephen C W ^a   Chan, Carmen W S ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Cardiac magnetic resonance imaging; Myocardial ischemia; Stress myocardial perfusion

Indexed keywords

DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RUBIDIUM 82; TECHNETIUM 99M; THALLIUM;

AORTA DISEASE; AREA UNDER THE CURVE; ARTICLE; CARDIAC IMAGING; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; FRACTIONAL FLOW RESERVE; GLOMERULUS FILTRATION RATE; HEART CONTRACTION; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; IMAGE ANALYSIS; LABORATORY DIAGNOSIS; MYOCARDIAL PERFUSION IMAGING; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RADIATION EXPOSURE; SENSITIVITY AND SPECIFICITY; SILENT MYOCARDIAL INFARCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 79952356260     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1269     Document Type: Article

References (59)

1. Schuijf JD, Poldermans D, Shaw LJ, Jukema JW, Lamb HJ, de Roos A, et al. Diagnostic and prognostic value of non-invasive imaging in known or suspected coronary artery disease. Eur J Nucl Med Mol Imaging 2006; 33: 93-104.
2. Usui Y, Chikamori T, Nakajima K, Hida S, Yamashina A, Nishimura T; J-ACCESS Investigators. Prognostic value of post-ischemic stunning as assessed by gated myocardial perfusion single-photon emission computed tomography: A subanalysis of the J-ACCESS study. Circ J 2010; 74: 1591-1599.
3. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42: 1318-1333.
4. Kitagawa K, Choi BW, Chan C, Jinzaki M, Tsai IC, Yong HS, et al. ASCI 2010 appropriateness criteria for cardiac magnetic resonance imaging: A report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group. Int J Cardiovasc Imaging 2010; 26(Suppl 2): 173-186.
5. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486.
6. Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med 2004; 350: 2438-2440.
7. Ishida M, Kato S, Sakuma H. Cardiac MRI in ischemic heart disease. Circ J 2009; 73: 1577-1588.
8. Hamon M, Fau G, Née G, Ehtisham J, Morello R, Hamon M. Metaanalysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson 2010; 12: 29.
9. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi N, Ahlstrom H, et al. MR-IMPACT: Comparison of perfusioncardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 2008; 29: 480-489.
10. Costa MA, Shoemaker S, Futamatsu H, Klassen C, Angiolillo DJ, Nguyen M, et al. Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. J Am Coll Cardiol 2007; 50: 514-522.
11. Rieber J, Huber A, Erhard I, Mueller S, Schweyer M, Koenig A, et al. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: A comparison with coronary angiography and fractional flow reserve. Eur Heart J 2006; 27: 1465-1471.
12. Kurita T, Sakuma H, Onishi K, Ishida M, Kitagawa K, Yamanaka T, et al. Regional myocardial perfusion reserve determined using myocardial perfusion magnetic resonance imaging showed a direct correlation with coronary flow velocity reserve by Doppler flow wire. Eur Heart J 2009; 30: 444-452.
13. Jerosch-Herold M. Quantification of myocardial perfusion by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010; 12: 57.
14. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, et al. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 2009; 120: 2207-2213.
15. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. WISE Investigators. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006; 47(Suppl): S4-S20.
16. Klem I, Greulich S, Heitner JF, Kim H, Vogelsberg H, Kispert EM, et al. Value of cardiovascular magnetic resonance stress perfusion testing for the detection of coronary artery disease in women. JACC Cardiovasc Imaging 2008; 1: 436-445.
17. Martin W, Tweddel AC, Hutton I. Balanced triple-vessel disease: Enhanced detection by estimated myocardial thallium uptake. Nucl Med Commun 1992; 13: 149-153.
18. Nygaard TW, Gibson RS, Ryan JM, Gascho JA, Watson DD, Beller GA. Prevalence of high-risk thallium-201 scintigraphic findings in left main coronary artery stenosis: Comparison with patients with multiple-and single-vessel coronary artery disease. Am J Cardiol 1984; 53: 462-469.
19. Chung SY, Lee KY, Chun EJ, Lee WW, Park EK, Chang HJ, et al. Comparison of stress perfusion MRI and SPECT for detection of myocardial ischemia in patients with angiographically proven threevessel coronary artery disease. Am J Roentgenol 2010; 195: 356-362.
20. Ishida M, Sakuma H, Kato N, Ishida N, Kitagawa K, Shimono T, et al. Contrast-enhanced MR imaging for evaluation of coronary artery disease before elective repair of aortic aneurysm. Radiology 2005; 237: 458-464.
21. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: A meta-analysis. J Am Coll Cardiol 2007; 50: 1343-1353.
22. Hundley WG, Hamilton CA, Thomas MS, Herrington DM, Salido TB, Kitzman DW, et al. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation 1999; 100: 1697-1702.
23. Paetsch I, Jahnke C, Ferrari VA, Rademakers FE, Pellikka PA, Hundley WG, et al. Determination of interobserver variability for identifying inducible left ventricular wall motion abnormalities during dobutamine stress magnetic resonance imaging. Eur Heart J 2006; 27: 1459-1464.
24. Jahnke C, Paetsch I, Gebker R, Bornstedt A, Fleck E, Nagel E. Accelerated 4D dobutamine stress MR imaging with k-t BLAST: Feasibility and diagnostic performance. Radiology 2006; 241: 718-728.
25. Kuijpers D, Ho KY, van Dijkman PR, Vliegenthart R, Oudkerk M. Dobutamine cardiovascular magnetic resonance for the detection of myocardial ischemia with the use of myocardial tagging. Circulation 2003; 107: 1592-1597.
26. Bree D, Wollmuth JR, Cupps BP, Krock MD, Howells A, Rogers J, et al. Low-dose dobutamine tissue-tagged magnetic resonance imaging with 3-dimensional strain analysis allows assessment of myocardial viability in patients with ischemic cardiomyopathy. Circulation 2006; 114(Suppl): I33-I36.
27. Dall'Armellina E, Morgan TM, Mandapaka S, Ntim W, Carr JJ, Hamilton CA, et al. Prediction of cardiac events in patients with reduced left ventricular ejection fraction with dobutamine cardiovascular magnetic resonance assessment of wall motion score index. J Am Coll Cardiol 2008; 52: 279-286.
28. Jahnke C, Nagel E, Gebker R, Kokocinski T, Kelle S, Manka R, et al. Prognostic value of cardiac magnetic resonance stress tests: Adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation 2007; 115: 1769-1776.
29. Bodi V, Sanchis J, Lopez-Lereu MP, Nunez J, Mainar L, Monmeneu JV, et al. Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll Cardiol 2007; 50: 1174-1179.
30. Pilz G, Jeske A, Klos M, Ali E, Hoefling B, Scheck R, et al. Prognostic value of normal adenosine-stress cardiac magnetic resonance imaging. Am J Cardiol 2008; 101: 1408-1412.
31. Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch-Herold M, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 2009; 120: 1390-1400.
32. Doesch C, Seeger A, Doering J, Herdeg C, Burgstahler C, Claussen CD, et al. Risk stratification by adenosine stress cardiac magnetic resonance in patients with coronary artery stenoses of intermediate angiographic severity. JACC Cardiovasc Imaging 2009; 2: 434-436.
33. Wallace EL, Morgan TM, Walsh TF, Dall'Armellina E, Ntim W, Hamilton CA, et al. Dobutamine cardiac magnetic resonance results predict cardiac prognosis in women with known or suspected ischemic heart disease. JACC Cardiovasc Imaging 2009; 2: 299-307.
34. Bodi V, Sanchis J, Lopez-Lereu MP, Nunez J, Mainar L, Monmeneu JV, et al. Prognostic and therapeutic implications of dipyridamole stress cardiovascular magnetic resonance on the basis of the ischaemic cascade. Heart 2009; 95: 49-55.
35. Korosoglou G, Elhmidi Y, Steen H, Schellberg D, Riedle N, Ahrens J, et al. Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive patients: Assessment of myocardial wall motion and perfusion. J Am Coll Cardiol 2010; 56: 1225-1234.
36. Lerakis S, McLean DS, Anadiotis AV, Janik M, Oshinski JN, Alexopoulos N, et al. Prognostic value of adenosine stress cardiovascular magnetic resonance in patients with low-risk chest pain. J Cardiovasc Magn Reson 2009; 11: 37.
37. Iskander S, Iskandrian AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 1998; 32: 57-62.
38. Ingkanisorn WP, Kwong RY, Bohme NS, Geller NL, Rhoads KL, Dyke CK, et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol 2006; 47: 1427-1432.
39. Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001; 345: 1863-1869.
40. Sakuma H, Ichikawa Y, Chino S, Hirano T, Makino K, Takeda K. Detection of coronary artery stenosis with whole-heart coronary magnetic resonance angiography. J Am Coll Cardiol 2006; 48: 1946-1950.
41. Clemente A, Del Borrello M, Greco P, Mannella P, Di Gregorio F, Romano S, et al. Anomalous origin of the coronary arteries in children: Diagnostic role of three-dimensional coronary MR angiography. Clin Imaging 2010; 34: 337-343.
42. Mavrogeni S, Papadopoulos G, Douskou M, Kaklis S, Seimenis I, Baras P, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol 2004; 43: 649-652.
43. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 2003; 361: 374-379.
44. Kühl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: Comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J 2006; 27: 846-853.
45. Patterson RE, Sigman SR, O'Donnell RE, Eisner RL. Viability assessment with MRI is superior to FDG-PET for viability: Con. J Nucl Cardiol 2010; 17: 298-309.
46. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-1453.
47. Wellnhofer E, Olariu A, Klein C, Gräfe M, Wahl A, Fleck E, et al. Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004; 109: 2172-2174.
48. Baer FM, Theissen P, Schneider CA, Voth E, Sechtem U, Schicha H, et al. Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998; 31: 1040-1048.
49. Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008; 118: 1011-1120.
50. Gutterman DD. Silent myocardial ischemia. Circ J 2009; 73: 785-797.
51. Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol 2010; 56: 1235-1243.
52. Prasad SR, Jagirdar J. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: A primer for radiologists. J Comput Assist Tomogr 2008; 32: 1-3.
53. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: Incidence, associations, and effect of risk factor assessment: Report of 33 cases. Radiology 2009; 250: 371-377.
54. Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008; 180: 830-835.
55. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC. Nephrogenic systemic fibrosis: Change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy: Report from two U.S. universities. Radiology 2009; 253: 689-696.
56. Mollerus M, Albin G, Lipinski M, Lucca J. Cardiac biomarkers in patients with permanent pacemakers and implantable cardioverterdefibrillators undergoing an MRI scan. Pacing Clin Electrophysiol 2008; 31: 1241-1245.
57. Pulver AF, Puchalski MD, Bradley DJ, Minich LL, Su JT, Saarel EV, et al. Safety and imaging quality of MRI in pediatric and adult congenital heart disease patients with pacemakers. Pacing Clin Electrophysiol 2009; 32: 450-456.
58. Levine GN, Gomes AS, Arai AE, Bluemke DA, Flamm SD, Kanal E, et al. American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Radiology and Intervention. Safety of magnetic resonance imaging in patients with cardiovascular devices: An American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: Endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation 2007; 116: 2878-2891.
59. Yoshinaga K, Manabe O, Tamaki N. Physiological assessment of myocardial perfusion using nuclear cardiology would enhance coronary artery disease patient care: Which imaging modality is best for evaluation of myocardial ischemia? (SPECT-Side) Circ J 2011; 75: 713-723.